The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about the treatment’s commercial success, the author sees this stock as a viable short candidate. For more, CLICK HERE.
A Short Biotech Idea
Tags:Biotech InvestmentsBiotech SectorFDAInvestmentsinvestorShort SqueezeSmall-Cap BiotechStock MarketstocksViable Short Stock Candidate